Pseudomonas aeruginosa

January 8, 2015November 6, 2015

Bronchiectasis Onset in CF Combatted with Azithromycin

Bronchiectasis, News

To “combat CF” and reduce bronchiectasis onset in the disease, researchers and clinicians at Queensland Children’s Medical Research Institute are currently recruiting patients for the “COMBATCF” clinical trial, “Prevention of ... Read more

January 7, 2015November 5, 2015

KaloBios’ Pseudomonas Aeruginosa Lung Infection Therapy Fails Study Primary Endpoint in CF Patients

Cystic Fibrosis, News

KaloBios Pharmaceuticals, Inc. announced that its potential treatment for Pseudomonas aeruginosa (Pa) lung infections was unable to meet the primary endpoint — “increased time to need for antibiotics for worsening respiratory tract ... Read more

December 29, 2014November 5, 2015

Quinsair Treatment For Pseudomonas Aeruginosa in Adult CF Patients Picks Up Positive CHMP Opinion

Cystic Fibrosis, News

The Committee for Medicinal Products for Human Use (CHMP) recently announced a positive comment for the pharmaceutical compound Quinsair, a nebuliser solution administered in a 240 mg dose, based on ... Read more

December 19, 2014December 19, 2014

Coming Soon: Smartwatch that Monitors SpO2 and Vital Signs in COPD

News

Wearable devices have been trending in the tech market, boasting hi-tech features that allow real-time fitness and body response tracking and syncing with one’s smartphone. Biomedical companies, such as Aseptika ... Read more

September 24, 2014November 6, 2015

Pseudomonas Leads to Bronchiectasis By Distracting Antibodies

Bronchiectasis, News

One of the obstacles that pharmaceutical companies and researchers face in the development of new therapeutics is bacterial mutation. Some medications take, on average, a decade of testing and rigorous ... Read more

July 2, 2014November 6, 2015

Study Reveals That Adherence To Treatment Affects Health Outcomes in Patients With Bronchiectasis

Bronchiectasis, News

A group of researchers from Queen’s University in Belfast, United Kingdom, recently published a study aiming to determine the level of adherence to inhaled antibiotics, other respiratory medicines and airway ... Read more

May 22, 2014November 6, 2015

Non-Cystic Fibrosis Bronchiectasis Drug Pulmaquin Receives QIDP Designation From FDA

Bronchiectasis

Aradigm Corporation’s experimental therapy Pulmaquin, an inhaled antibiotic for the treatment of non-cystic fibrosis bronchiectasis, was recently given the Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). The ... Read more